Objective: To investigate the therapeutic effect and potential mechanism of modified citrus pectin (MCP) in the treatment of rheumatoid arthritis with interstitial lung disease (RA-ILD). Methods: The RA-ILD mouse model was established and divided into control group, model group and MCP treatment group. Lung tissue was taken for pathological section. The other part of lung tissue was subjected to transcriptome sequencing and subsequent bioinformatics analysis. Results: MCP could improve the pathological changes of pulmonary fibrosis in RA-ILD mice. A total of 23 core genes for drug intervention were screened, of which the expression of 9 homologous genes in humans was consistent with the expression trend in mice, which were LCK, THY1, GZMA, CXCR3, LR10RA, CCL5, CTLA4, CD19, and CD5. The enrichment functions and pathways revealed that pathways such as T cell activation regulation, cell adhesion regulation, immune receptor activity, Th17 cell differentiation, and Th1 and Th2 cell differentiation played an important role in MCP treatment of fibrosis. Conclusion: (1) MCP has a definite therapeutic effect on RA-ILD mice, which can significantly improve the severity of pulmonary fibrosis and the degree of inflammatory cell infiltration in lung tissue; (2) There are 23 core genes that play a key role in the treatment of diseases, including 9 human homologous genes; (3) Core genes play a role through T cell activation regulation, cell adhesion regulation, immune receptor activity, Th17 cell differentiation, Th1 and Th2 cell differentiation.
WANG Guan
,
GENG Lixia
,
BAI Li
,
HUO Yinping
,
LIU Jing
,
MA Wen
. Transcriptome analysis of MCP in the treatment of rheumatoid arthritis with pulmonary fibrosis[J]. Journal of Baotou Medical College, 2024
, 40(9)
: 29
-35
.
DOI: 10.16833/j.cnki.jbmc.2024.09.006
[1] Wildhagen KC,Lutgens E,Loubele ST,et al. The structure-function relationship of activated protein C.Lessons from natural and engineered mutations[J]. Thromb Haemost,2011,6:1034-1045.
[2] Griffin JH,Zlokovic BV,Mosnier LO. Activated protein C: biased for translation[J]. Blood,2015,125(19):2898-2907.
[3] Bernard GR,Vincent JL,Laterre PF,et al. Efficacy and safety of recombinant human activated protein C for severe sepsis[J]. N Engl J Med,2001,344(10):699-709.
[4] Martí-Carvajal AJ,Solà I,Gluud C,et al. Human recombinant protein C for severe sepsis and septic shock in adult and paediatric patients[J]. Cochrane Database Syst Rev,2012,12(12):CD004388.
[5] 邓晓玲,许飞.特发性肺纤维化发病机制研究进展[J].实用临床医学,2020,21(10):102-106.
[6] 中华医学会呼吸病学分会间质性肺病学组,中国医师协会呼吸医师分会间质性肺疾病工作委员会.特发性肺纤维化急性加重诊断和治疗中国专家共识[J]. 中华医学杂志,2019,99(26):2014-2023.
[7] Raghu G,Remy-Jardin M,Richeldi L,et al. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS/ERS/JRS/ALAT clinical practice guideline[J]. Am J Respir Crit Care Med,2022,205(9):e18-e47.
[8] Bellaye P S,Yanagihara T,Granton E,et al. Macitentan reduces progression of TGF-β1-induced pulmonary fibrosis and pulmonary hypertension[J]. Eur Respir J,2018,52(2):1701857.
[9] Habermann AC,Gutierrez AJ,Bui L T,et al. Single-cell RNA sequencing reveals profibrotic roles of distinct epithelial and mesenchymal lineages in pulmonary fibrosis[J]. Sci Adv,2020,6(28):eaba1972.
[10] Mehrzadi S,Hosseini P,Mehrabani M,et al. Attenuation of bleomycin-induced pulmonary fibrosis in wistar rats by combination treatment of two natural phenolic compounds: quercetin and Gallic acid[J]. Nutr Cancer,2021,73(10):2039-2049.
[11] Yamakawa H,Ogura T,Kameda H,et al. Decision-making strategy for the treatment of rheumatoid arthritis-associated interstitial lung disease (RA-ILD)[J]. J Clin Med,2021,10(17):3806.
[12] Dai YJ,Wang WN,Yu YK,et al. Rheumatoid arthritis-associated interstitial lung disease: an overview of epidemiology,pathogenesis and management[J]. Clin Rheumatol,2021,40(4):1211-1220.
[13] Arrieta V,Sádaba J R,álvarez V,et al. Galectin-3 as a novel biotarget in cardiovascular alterations associated to development of severe aortic stenosis[J]. An Sist Sanit Navar,2019,42(2):199-208.
[14] Calvier L,Miana M,Reboul P,et al. Galectin-3 mediates aldosterone-induced vascular fibrosis[J]. Arterioscler Thromb Vasc Biol,2013,33(1):67-75.
[15] Arrieta V,Martinez-Martinez E,Ibarrola J,et al. A role for galectin-3 in the development of early molecular alterations in short-term aortic stenosis[J]. Clin Sci,2017,131(10):935-949.
[16] Calvier L,Martinez-Martinez E,Miana M,et al. The impact of galectin-3 inhibition on aldosterone-induced cardiac and renal injuries[J]. JACC Heart Fail,2015,3(1):59-67.
[17] Kim JI,Jang HS,Jeong JH,et al. Defect in Runx2 gene accelerates ureteral obstruction-induced kidney fibrosis via increased TGF-β signaling pathway[J]. Biochim Biophys Acta,2013,1832(10):1520-1527.
[18] Xu GR,Zhang C,Yang HX,et al. Modified citrus pectin ameliorates myocardial fibrosis and inflammation via suppressing galectin-3 and TLR4/MyD88/NF-κB signaling pathway[J]. Biomed Pharmacother,2020,126:110071.
[19] Mo D,Tian W,Zhang H N,et al. Cardioprotective effects of galectin-3 inhibition against ischemia/reperfusion injury[J]. Eur J Pharmacol,2019,863:172701.
[20] Boscher C,Nabi IR. Galectin-3- and phospho-caveolin-1-dependent outside-in integrin signaling mediates the EGF motogenic response in mammary cancer cells[J]. Mol Biol Cell,2013,24(13):2134-2145.
[21] Boscher C,Zheng YZ,Lakshminarayan R,et al. Galectin-3 protein regulates mobility of N-cadherin and GM1 ganglioside at cell-cell junctions of mammary carcinoma cells[J]. J Biol Chem,2012,287(39):32940-32952.
[22] Blanda V,Bracale UM,DI Taranto MD,et al. Galectin-3 in cardiovascular diseases[J]. Int J Mol Sci,2020,21(23):9232.
